Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
abuse, AETHERA, Affordability, Affordable, AMRI, anemia, answer, area, back, Baxter, biosimilar, bring, budget, confirmatory, constitute, convene, CTCL, depleted, digit, disaster, disrupted, disruption, dividing, dollar, drafted, earliest, education, efficiency, eleven, England, entry, EP, export, Factor, False, fire, Folotyn, fraud, GAAP, gastric, Genmab, imprisonment, includingin, indolent, Istodax, jeopardized, Journal, jurisdiction, knowingly, licensure, lifted, Lonza, Medicaid, Medicare, medicine, narrow, NHL, offsite, ordinary, PDUFA, physically, pill, poison, Prescription, President, pronouncement, radiation, referral, refusing, regularly, relevant, remuneration, respiratory, role, Rule, salvage, SEER, sensory, shutdown, soliciting, Statute, theNew, thereunder, thirty, thrombocytopenia, tract, train, twenty, undergo, Union, unsuccessful, upper, view, widespread, willingly
Removed:
abnormal, absence, accept, accumulation, activating, added, advancement, age, antidilutive, apply, AstraZeneca, automatic, Avastin, bacteria, Bexxar, billion, bind, BioPharma, bleeding, blind, bone, bound, bypassing, Campath, capable, carboplatin, category, Certificate, challenging, CHEF, Clolar, combine, conference, convert, converted, convertible, created, cure, Dacogen, daunorubicin, death, decision, deduction, deficiency, designation, desire, die, diversified, DLBCL, donor, double, EGFR, Eli, employed, employing, ending, engineered, entity, Erbitux, etoposide, evaluable, explore, Felix, filled, Gemzar, generation, genetically, goal, Herceptin, humanizing, hybrid, hypomethylating, ideally, ifosfamide, immature, improved, increasingly, incurable, India, ineligible, inhibit, inhibiting, initiation, Institute, intensive, intermediate, judicial, kill, Lilly, linking, liquidated, malignancy, manage, marrow, MDS, MedImmune, mitoxantrone, morbidity, myelodysplastic, myeloproliferative, Mylotarg, neutralize, neutralizing, nonexclusive, notably, Note, onset, par, payload, PDL, percentage, pool, presence, progression, prolong, red, release, restore, selectivity, sending, signal, slightly, suited, sustainable, tolerate, transforming, transfusion, transplantation, uncontrolled, underway, unmet, Vectibix, VEGF, vialing, white, windfall, Zevalin
Filing tables
Filing exhibits
- 10-K Annual report
- 10.14 Amended and Restated 2000 Employee Stock Purchase Agreement
- 10.33 Compensation Information for Executive Officers and Directors
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32.1 Section 906 CEO Certification
- 32.2 Section 906 CFO Certification
Related press release
SGEN similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-56670, 333-148188, and 333-168672) of Seattle Genetics, Inc., and in the Registration Statement on Form S-3 (File No. 333-159457) of Seattle Genetics, Inc. and in the related Prospectus, of our report dated February 28, 2011 relating to the consolidated financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Seattle, Washington
February 28, 2011